Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: A review of published evidence

BMC Urology

Volumn 9, Issue 1, 2009, Pages

  Campbell, Jonathan D ^a,b   Gries, Katharine S ^a   Watanabe, Jonathan H ^a   Ravelo, Arliene ^c   Dmochowski, Roger R ^d   Sullivan, Sean D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c ALLERGAN INC   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; BLADDER RECONSTRUCTION; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INTERVENTION STUDY; NEUROMODULATION; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME; URGE INCONTINENCE; URINARY FREQUENCY; ANIMAL; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 72849108462     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-9-18     Document Type: Article

References (70)

1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. P Abrams L Cardozo M Fall D Griffiths P Rosier U Ulmsten P Van Kerrebroeck A Victor A Wein, Urology 2003 61 1 37 49
2. Prevalence and burden of overactive bladder in the United States. WF Stewart JB Van Rooyen GW Cundiff P Abrams AR Herzog R Corey TL Hunt AJ Wein, World journal of urology 2003 20 6 327 336 (Pubitemid 44175300)
3. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. L Brubaker C Chapple KS Coyne Z Kopp, Urology 2006 68 2 Suppl 3 8 (Pubitemid 44189491)
4. Comorbidities associated with overactive bladder. JS Brown WF McGhan S Chokroverty, The American journal of managed care 2000 6 11 Suppl 574 579
5. Overactive bladder and women's sexual health: what is the impact? KS Coyne MK Margolis Z Jumadilova T Bavendam E Mueller R Rogers, The journal of sexual medicine 2007 4 3 656 666
6. Estimated economic costs of overactive bladder in the United States. TW Hu TH Wagner JD Bentkover K LeBlanc A Piancentini WF Stewart R Corey SZ Zhou TL Hunt, Urology 2003 61 6 1123 1128 (Pubitemid 36693985)
7. Bladder training for urinary incontinence in adults. SA Wallace B Roe K Williams M Palmer, Cochrane Database Syst Rev 2004 1 CD001308
8. Behavioral therapies for overactive bladder: making sense of the evidence. JL Milne, J Wound Ostomy Continence Nurs 2008 35 1 93 101 quiz 102-103
9. Muscarinic receptor antagonists for overactive bladder. P Abrams KE Andersson, BJU Int 2007 100 5 987 1006
10. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. G Nabi JD Cody G Ellis P Herbison J Hay-Smith, Cochrane Database Syst Rev 2006 4 CD003781
11. Cost Analysis of Overactive Bladder Treatments for Oral Antimuscarinic Refractory Patients. JH Watanabe JD Campbell, et al. American Urological Association: 2008; Orlando, FL 2008
12. Botulinum toxin A in the overactive bladder: current status and future directions. R Dmochowski PK Sand, BJU Int 2007 99 2 247 262
13. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. B Schurch M de Seze P Denys E Chartier-Kastler F Haab K Everaert P Plante B Perrouin-Verbe C Kumar S Fraczek, et al. The Journal of urology 2005 174 1 196 200
14. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). DL Patrick ML Martin DM Bushnell I Yalcin TH Wagner DP Buesching, Urology 1999 53 1 71 76
15. The estimation of a preference-based measure of health from the SF-36. J Brazier J Roberts M Deverill, J Health Econ 2002 21 2 271 292
16. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. B Schurch P Denys CM Kozma PR Reese T Slaton R Barron, Arch Phys Med Rehabil 2007 88 5 646 652 (Pubitemid 46656251)
17. Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence. I Yalcin DL Patrick K Summers K Kinchen RC Bump, Urology 2006 67 6 1304 1308
18. Botulinum toxin injections for adults with overactive bladder syndrome. J Duthie DI Wilson GP Herbison D Wilson, Cochrane Database Syst Rev 2007 3 CD005493
19. Botulinum toxin for the management of bladder dysfunction. B Schurch, Drugs 2006 66 10 1301 1318 (Pubitemid 44246615)
20. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. M Brazzelli A Murray C Fraser, The Journal of urology 2006 175 3 Pt 1 835 841
21. Surgical and patient reported outcomes of 'clam' augmentation ileocystoplasty in spinal cord injured patients. J Khastgir R Hamid M Arya N Shah PJ Shah, Eur Urol 2003 43 3 263 269
22. Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. WW Leng HJ Blalock WH Fredriksson SF English EJ McGuire, The Journal of urology 1999 161 3 758 763
23. Redefining response in overactive bladder syndrome. CK Payne C Kelleher, BJU Int 2007 99 1 101 106 (Pubitemid 44915628)
24. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. CR Chapple W Artibani LD Cardozo D Castro-Diaz M Craggs F Haab V Khullar E Versi, BJU Int 2005 95 3 335 340
25. Reductions in stress urinary incontinence episodes: What is clinically important for Women? I Yalcin G Peng L Viktrup RC Bump, Neurourol Urodyn 2009
26. Botulinum-A toxin injection into the detrusor as treatment for refractory detrusor hypperreflexia. M Kennelly J Kang, Top Spinal Cord Inj Rehabil 2003 8 46 53
27. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. A Reitz M Stohrer G Kramer G Del Popolo E Chartier-Kastler J Pannek H Burgdorfer K Gocking H Madersbacher S Schumacher, et al. Eur Urol 2004 45 4 510 515
28. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. A Giannantoni SM Di Stasi RL Stephen V Bini E Costantini M Porena, The Journal of urology 2004 172 1 240 243
29. New therapeutic options for refractory neurogenic detrusor overactivity. A Giannantoni E Mearini SM Di Stasi E Costantini A Zucchi L Mearini P Fornetti M Del Zingaro P Navarra M Porena, Minerva Urol Nefrol 2004 56 1 79 87
30. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. J Klaphajone W Kitisomprayoonkul S Sriplakit, Arch Phys Med Rehabil 2005 86 11 2114 2118
31. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? TM Kessler H Danuser M Schumacher UE Studer FC Burkhard, Neurourol Urodyn 2005 24 3 231 236
32. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. R Popat A Apostolidis V Kalsi G Gonzales CJ Fowler P Dasgupta, The Journal of urology 2005 174 3 984 989
33. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. M Werner DM Schmid B Schussler, Am J Obstet Gynecol 2005 192 5 1735 1740
34. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? HC Kuo, Urology 2006 68 5 993 997 discussion 997-998
35. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. A Giannantoni SM Di Stasi V Nardicchi A Zucchi L Macchioni V Bini G Goracci M Porena, The Journal of urology 2006 175 6 2341 2344
36. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. G Karsenty A Reitz G Lindemann S Boy B Schurch, Urology 2006 68 6 1193 1197
37. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. A Sahai MS Khan P Dasgupta, The Journal of urology 2007 177 6 2231 2236
38. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. F Mascarenhas M Cocuzza CM Gomes N Leao, Neurourol Urodyn 2008 27 4 311 314
39. Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study. JL Bosch J Groen, The Journal of urology 2000 163 4 1219 1222
40. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. EJ Chartier-Kastler JL Ruud Bosch M Perrigot MB Chancellor F Richard P Denys, The Journal of urology 2000 164 5 1476 1480
41. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. EH Weil JL Ruiz-Cerda PH Eerdmans RA Janknegt BL Bemelmans PE van Kerrebroeck, Eur Urol 2000 37 2 161 171
42. Chronic sacral neuromodulation in patients with lower urinary tract symptoms: results from a national register. M Spinelli P Bertapelle F Cappellano A Zanollo R Carone F Catanzaro G Giardiello F De Seta, The Journal of urology 2001 166 2 541 545
43. Long-term results of augmentation cystoplasty in spinal cord injury patients. EJ Chartier-Kastler P Mongiat-Artus MO Bitker MB Chancellor F Richard P Denys, Spinal Cord 2000 38 8 490 494
44. Review of augmentation 'clam' cystoplasy in a district general hospital setting. KD Ivil G Suresh, Int Urol Nephrol 2002 34 1 129 132
45. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. ML Quek DA Ginsberg, The Journal of urology 2003 169 1 195 198
46. Outcome of urethral closure in patients with neurologic impairment and complete urethral destruction. JT Stoffel EJ McGuire, Neurourol Urodyn 2006 25 1 19 22
47. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. MK Flynn GD Webster CL Amundsen, The Journal of urology 2004 172 6 Pt 1 2316 2320
48. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. HC Kuo, Urology 2004 63 5 868 872
49. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. HC Kuo, Urology 2005 66 1 94 98
50. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. V Kalsi RB Popat A Apostolidis R Kavia IA Odeyemi HA Dakin J Warner S Elneil CJ Fowler P Dasgupta, Eur Urol 2006 49 3 519 527
51. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. V Kalsi G Gonzales R Popat A Apostolidis S Elneil P Dasgupta CJ Fowler, Annals of neurology 2007 62 5 452 457
52. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. RA Schmidt U Jonas KA Oleson RA Janknegt MM Hassouna SW Siegel PE van Kerrebroeck, The Journal of urology 1999 162 2 352 357
53. Sacral neuromodulation in an older, urge-incontinent population. CL Amundsen GD Webster, Am J Obstet Gynecol 2002 187 6 1462 1465 discussion 1465
54. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. MM Hassouna SW Siegel AA Nyeholt MM Elhilali PE van Kerrebroeck AK Das JB Gajewski RA Janknegt DA Rivas H Dijkema, et al. The Journal of urology 2000 163 6 1849 1854
55. Urodynamic results of sacral neuromodulation correlate with subjective improvement in patients with an overactive bladder. WA Scheepens GA van Koeveringe RA de Bie EH Weil PE van Kerrebroeck, Eur Urol 2003 43 3 282 287
56. Medium-term experience of sacral neuromodulation by tined lead implantation. AC Van Voskuilen DJ Oerlemans EH Weil U van den Hombergh PE van Kerrebroeck, BJU Int 2007 99 1 107 110
57. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. PM Groenendijk AA Lycklama a Nyeholt JP Heesakkers PE van Kerrebroeck MM Hassouna JB Gajewski F Cappellano SW Siegel M Fall HE Dijkema, et al. BJU Int 2008 101 3 325 329
58. Sacral nerve neuromodulation in patients with underlying neurologic disease. PA Wallace FL Lane KL Noblett, Am J Obstet Gynecol 2007 197 1 91 95
59. Long-term followup of augmentation enterocystoplasty and continent diversion in patients with benign disease. JG Blaivas JP Weiss P Desai AJ Flisser DS Stember PJ Stahl, The Journal of urology 2005 173 5 1631 1634
60. Botulinum-A toxin destrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence [abstract]. A Loch T Loct J Osterhage, et al. Eur Urol Suppl 2003 2 1 172
61. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. DE Rapp A Lucioni EE Katz RC O'Connor GS Gerber GT Bales, Urology 2004 63 6 1071 1075
62. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. J Grosse G Kramer M Stohrer, Eur Urol 2005 47 5 653 659
63. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. GN Rajkumar DR Small AW Mustafa G Conn, BJU Int 2005 96 6 848 852
64. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. H Schulte-Baukloh C Weiss T Stolze J Herholz B Sturzebecher K Miller HH Knispel, Eur Urol 2005 48 6 984 990 discussion 990 (Pubitemid 41641650)
65. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. DM Schmid P Sauermann M Werner B Schuessler N Blick M Muentener RT Strebel D Perucchini D Scheiner G Schaer, et al. The Journal of urology 2006 176 1 177 185
66. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. H Schulte-Baukloh J Schobert T Stolze B Sturzebecher C Weiss HH Knispel, Neurourol Urodyn 2006 25 2 110 115
67. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. HC Kuo, The Journal of urology 2007 178 4 Pt 1 1359 1363
68. Clam ileocystoplasty: successful treatment of severe bladder overactivity. C Edlund R Peeker M Fall, Scand J Urol Nephrol 2001 35 3 190 195
69. Bladder augmentation using Pelvicol implant for intractable overactive bladder syndrome. JW Barrington R Dyer F Bano, Int Urogynecol J Pelvic Floor Dysfunct 2006 17 1 50 53
70. Augmentation ileocystoplasty in patients with neurogenic bladder due to spinal cord injury or spina bifida. S Nomura T Ishido K Tanaka A Komiya, Spinal Cord 2002 40 1 30 33